GLIM 3/MG TAB 30/TAB

Indications

Approved Uses

Type 2 diabetes mellitus in adults as an adjunct to diet and exercise, either as monotherapy or in combination with metformin or insulin

Dosage & Administration

Dosing by Condition

Type 2 diabetes mellitus: Initial 1-2 mg once daily with breakfast; maintenance 1-4 mg once daily; maximum 8 mg once daily

Initial Dose

1-2 mg once daily with first main meal

Maintenance Dose

1-4 mg once daily

Maximum Dose

8 mg once daily

Children's Dosage

Not recommended for children

Dose Adjustment Notes

Titrate in increments of 1-2 mg at 1-2 week intervals based on blood glucose response. Use with caution and start at lowest dose in renal or hepatic impairment. Dose reduction may be required when adding to insulin therapy

Side Effects

Common Side Effects

Hypoglycemia, nausea, vomiting, diarrhea, abdominal pain, headache, dizziness, weight gain

Safety & Warnings

Contraindications

Type 1 diabetes mellitus, diabetic ketoacidosis, diabetic coma or pre-coma, severe renal impairment, severe hepatic impairment, hypersensitivity to glimepiride or other sulfonylureas or sulfonamides, pregnancy, breastfeeding

Warnings & Precautions

Risk of severe hypoglycemia especially in elderly, malnourished, or renally impaired patients; monitor blood glucose regularly; caution in G6PD deficiency (risk of hemolytic anemia); may cause weight gain; cross-sensitivity with sulfonamides possible; stress, fever, trauma, or surgery may alter glycemic control requiring dose adjustment; avoid abrupt discontinuation without medical supervision

Age Restriction

Not approved under 18 years

Drug Interactions

Drug Interactions

NSAIDs (enhanced hypoglycemic effect), fluconazole and other CYP2C9 inhibitors (increased glimepiride levels), rifampicin (reduced efficacy), beta-blockers (mask hypoglycemia symptoms), ACE inhibitors (potentiate hypoglycemia), warfarin (altered anticoagulant effect), MAO inhibitors (enhanced hypoglycemia), alcohol (unpredictable glucose effect), corticosteroids (antagonize hypoglycemic effect), thiazide diuretics (reduce efficacy), miconazole (severe hypoglycemia risk)

Food Interaction

Take with first main meal of the day; skipping a meal after taking the dose increases hypoglycemia risk

Special Populations

Pregnancy

Contraindicated

Children

Not recommended for children

Elderly

Start at 1 mg once daily, titrate slowly with careful blood glucose monitoring due to increased risk of hypoglycemia; renal function should be assessed before and during treatment

Kidney Impairment

Mild-moderate renal impairment: start at 1 mg once daily, titrate cautiously. Severe renal impairment: contraindicated

Storage & Patient Advice

Overdose

Symptoms: severe prolonged hypoglycemia including loss of consciousness, seizures, neurological impairment. Management: immediate oral glucose if conscious, intravenous glucose (50% dextrose bolus followed by 10% dextrose infusion) if unconscious, close monitoring of blood glucose for at least 24-48 hours, seek immediate emergency medical attention

Patient Counseling

Take this tablet with your first main meal every day and never skip a meal after taking it. Learn to recognize hypoglycemia symptoms such as sweating, shaking, dizziness, and confusion - always carry glucose tablets or sugar. Monitor your blood sugar regularly and keep a log. Avoid alcohol as it can unpredictably affect your blood sugar. Inform your doctor or pharmacist about all other medications including OTC drugs. Do not stop taking this medication without consulting your doctor. Maintain your prescribed diet and exercise plan. Inform your healthcare provider if you are planning surgery, have an illness, or experience unusual stress as dose adjustments may be needed.

Monitoring Requirements

Regular fasting and postprandial blood glucose monitoring, HbA1c every 3 months, renal function tests periodically, liver function tests periodically, complete blood count periodically

Pharmacology

Mechanism of Action

Stimulates insulin secretion from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels, leading to membrane depolarization, calcium influx, and insulin release; also enhances peripheral insulin sensitivity

Onset of Action

2-3 hours

Duration of Effect

24 hours

Half-Life

5.3 hours

Metabolism

Hepatic via CYP2C9 to active metabolite M1 (cyclohexyl hydroxy methyl derivative) and inactive metabolite M2

Protein Binding

>99%

Product Information

Available Dosage Forms

Tablet

Composition per Dose

Each tablet: 3 mg glimepiride

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Diabetes Type

Type 2

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.